financetom
Business
financetom
/
Business
/
Stellantis plans output, price cuts after weak H1 results
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stellantis plans output, price cuts after weak H1 results
Jul 25, 2024 1:25 AM

MILAN (Reuters) -Stellantis pledged on Thursday to take steps to address problems in North American and elsewhere, including cutting output and prices, after the world's No. 4 carmaker delivered worse-than-expected first-half results, sending its shares down 10%.

"The company's performance in the first half of 2024 fell short of our expectations," CEO Carlos Tavares said in a statement.

Adjusted operating income (EBIT) fell 40% to 8.463 billion euros ($9.17 billion) in the half year to June 30, below the 8.85 billion euros expected by analysts in a Reuters poll.

The results pile more pressure on Tavares to revive flagging margins and sales and cut inventory in the United States as the carmaker bets on the launch of 20 new models this year which it hopes will boost profitability.

Its Milan-listed shares were down about 8% after earlier hitting their lowest since August 2023. They have lost 20% of their value this year, making them the worst performer among the major European carmakers.

Its margin on adjusted EBIT shrunk to just below 10%, slipping below the double-digit margin it aims to achieve for the full year.

Stellantis' free cash flow was negative at almost 400 million euros in the first half.

"We are working hard to meet our full-year (adjusted operating income) margin forecast and to deliver positive cash flows in the second half," CFO Natalie Knight told a media roundtable.

Stellantis forecast include positive industrial free cash flow for the year.

Stellantis said it was taking "decisive actions to address operational challenges" and CFO Knight said that, looking at the second half, the group was taking "the bulls by the horns".

She said measures include inventory reduction and logistics, especially in North America, the group's profit powerhouse.

"(That) is the market that needs the most work and where we are most concentrated when we look at the second half," Knight said.

"There are operational issues we've had in North America where I think we could have performed stronger".

The CFO added the group would reduce production in North America this quarter, as well as prices.

"That's one of the things that is important for us, to calibrate how the supply and demand meet," she said.

Analysts at Citi said in a note they expect Stellantis problems to continue.

"We see no real improvement until and unless Stellantis removes the overhang from inventories - which itself would put pressure on full-year ...margins," they wrote.

Japan's Nissan Motor saw first-quarter profit almost completely wiped out on Thursday and slashed its annual outlook, as deep discounting in the United States shredded its margins.

($1 = 0.9226 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CERAWEEK-Exxon ahead of schedule on doubling LNG portfolio, exec says
CERAWEEK-Exxon ahead of schedule on doubling LNG portfolio, exec says
Mar 21, 2024
HOUSTON, March 21 (Reuters) - Exxon Mobil ( XOM ) is ahead of schedule with its plan to double the size of its liquefied natural gas (LNG) portfolio to 40 million tons per annum (mtpa) by 2030 and will focus on selling its own gas rather than trading that of third parties, the company's LNG chief said on Thursday. Exxon...
US FDA approves Italfarmaco's drug for Duchenne muscle-wasting disorder
US FDA approves Italfarmaco's drug for Duchenne muscle-wasting disorder
Mar 21, 2024
By Mariam Sunny and Sruthi Narasimha Chari March 21 (Reuters) - The U.S. FDA has approved privately held Italfarmaco Group's drug to treat Duchenne muscular dystrophy (DMD), an inherited muscle-wasting disorder, the health regulator said on Thursday. The oral drug, to be sold under the brand name Duvyzat, is the first nonsteroidal drug approved to treat patients with all genetic...
Oil eases on possible Gaza ceasefire, dollar strength
Oil eases on possible Gaza ceasefire, dollar strength
Mar 21, 2024
SINGAPORE (Reuters) -Oil prices slipped on Friday on the possibility of a nearing Gaza ceasefire that could ease geopolitical concerns in the Middle East, while a stronger dollar and faltering U.S. gasoline demand also weighed on prices. Brent crude futures fell 42 cents, or 0.5%, to $85.36 a barrel by 0203 GMT. U.S. crude futures shed 40 cents, or 0.5%,...
Meta's Instagram down for thousands, Downdetector shows
Meta's Instagram down for thousands, Downdetector shows
Mar 21, 2024
March 21 (Reuters) - Meta Platforms's ( META ) Instagram was down for thousands of users on Thursday, according to outage tracking website Downdetector.com. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved